Paul B. Laub
About
In The Last Decade
Paul B. Laub
11 papers receiving 742 citations
Peers
Comparison fields: 5 of 81
- Molecular Biology 388
- Oncology 250
- Reproductive Medicine 217
- Genetics 103
- Pathology and Forensic Medicine 94
Countries citing papers authored by Paul B. Laub
This map shows the geographic impact of Paul B. Laub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul B. Laub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul B. Laub more than expected).
Fields of papers citing papers by Paul B. Laub
This network shows the impact of papers produced by Paul B. Laub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul B. Laub. The network helps show where Paul B. Laub may publish in the future.
Co-authorship network of co-authors of Paul B. Laub
This figure shows the co-authorship network connecting the top 25 collaborators of Paul B. Laub. A scholar is included among the top collaborators of Paul B. Laub based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul B. Laub. Paul B. Laub is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 121 | |
| 2 | 54 | |
| 3 | Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose. | 16 |
| 4 | 20 | |
| 5 | Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. | 151 |
| 6 | 50 | |
| 7 | 210 | |
| 8 | Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. | 11 |
| 9 | 16 | |
| 10 | Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. | 24 |
| 11 | 84 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.